Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol

  • Tell a FriendPrint

Assess the efficacy of WelChol® plus Zetia® in treating patients with high...

Brief Summary

Official Title: “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Combination With Zetia® Compared to Zetia® Alone in Patients With Primary Hypercholesterolemia”

Assess the efficacy of WelChol® plus Zetia® in treating patients with high cholesterol

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Intervention(s) in this Clinical Trial

  • Drug: Colesevelam Hydrochloride
  • Drug: Ezetimibe
  • Drug: Simvastatin

Outcome Measures for this Clinical Trial

Primary Measures

  • The percent change in LDL-C from the start of the study

Secondary Measures

  • - The absolute change in LDL-C from baseline
  • - The percent change in LDL-C from baseline
  • - The absolute changes and percent changes in TG, non-HDL-
  • C, HDL-C, total cholesterol and other lipid measures
  • - The percentages of patients who achieve target levels of LDL-C at the end of the study

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • 18-80 years of age, inclusive;
  • A history of primary hypercholesterolemia

Exclusion Criteria:

  • Any serious disorders including pulmonary, hepatic, renal, gastrointestinal (including clinically significant malabsorption), uncontrolled endocrine/ metabolic, hematologic/oncologic (within the last 5 years), neurologic and psychiatric diseases that would interfere with the conduct of the study or interpretation of the data;
  • Hepatic dysfunction including biliary cirrhosis, unexplained persistent liver function abnormality, and pre-existing gallbladder disease

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 80 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Investigator Information

Lead Investigator: Daiichi Sankyo Inc. Industry

Additional Information

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00185107

Study ID Number: WEL-408

ClinicalTrials.gov Identifier: NCT00185107

Health Authority: United States: Food and Drug Administration

  • Tell a FriendPrint

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00185107